A Comprehensive Review of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors: Unpacking Pleiotropic Effects and Expanding Therapeutic Horizons

Many thanks to our sponsor Esdebe who helped us prepare this research report.

Abstract

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, colloquially known as gliflozins, have fundamentally reshaped the landscape of metabolic and cardiovascular medicine. Initially introduced for their potent glucose-lowering capabilities in type 2 diabetes mellitus (T2DM), their clinical utility has dramatically broadened to encompass profound cardiovascular and renal protection, independent of glycemic status. This extensive review meticulously examines the intricate and multifaceted mechanisms underpinning these pleiotropic effects, offering a detailed exploration of their diverse therapeutic applications across an evolving spectrum of patient populations and disease states. Furthermore, it scrutinizes the ongoing frontiers of research, including novel applications in emerging clinical contexts, the nuanced understanding of their long-term safety profiles, and their evolving role in personalized medicine, providing an up-to-date synthesis of their transformative impact on clinical practice.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

The global prevalence of type 2 diabetes mellitus (T2DM) continues to escalate, posing a significant public health challenge due to its association with severe microvascular and macrovascular complications, including cardiovascular disease (CVD) and chronic kidney disease (CKD). For decades, pharmacological interventions primarily focused on reducing hyperglycemia through various mechanisms, such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production. Despite these advancements, a substantial residual risk of cardiovascular and renal events persisted, highlighting an unmet need for therapies that could address these critical comorbidities more comprehensively [11].

SGLT2 inhibitors, a novel class of oral antidiabetic agents, emerged from this therapeutic imperative. The initial gliflozins, including empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin, received regulatory approval based on their unique glucose-lowering mechanism [6, 7, 8, 9]. Unlike previous agents, SGLT2 inhibitors operate by selectively inhibiting the SGLT2 protein, predominantly found in the S1 segment of the proximal renal tubules. This inhibition blocks approximately 90% of glucose reabsorption from the glomerular filtrate, leading to increased urinary glucose excretion (glucosuria) [10]. This mechanism not only effectively lowers blood glucose concentrations but also elicits secondary effects, including modest osmotic diuresis, natriuresis, and a consequent reduction in blood pressure and body weight [1].

What began as a targeted therapy for glycemic control in T2DM has evolved into a cornerstone treatment for cardiorenal protection. Landmark cardiovascular outcome trials (CVOTs), such as EMPA-REG OUTCOME, CANVAS Program, and DECLARE-TIMI 58, unequivocally demonstrated that SGLT2 inhibitors significantly reduce the risk of hospitalization for heart failure (HHF), cardiovascular death, and the progression of CKD, often irrespective of the patient’s baseline glycemic control or history of diabetes [2, 3]. These groundbreaking findings have profoundly reshaped clinical guidelines, positioning SGLT2 inhibitors as pivotal agents in the integrated management of T2DM, heart failure (HF) with both reduced and preserved ejection fraction (HFrEF and HFpEF), and CKD across various etiologies. The subsequent DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, DAPA-CKD, and EMPA-KIDNEY trials further solidified and expanded these indications, confirming benefits across a broader spectrum of patients [12, 13, 14, 15, 16]. This paradigm shift underscores a deeper understanding of the complex interplay between metabolic, cardiovascular, and renal systems and highlights the pleiotropic benefits of SGLT2 inhibition.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Mechanisms of Action: Unraveling the Pleiotropic Effects

The profound cardiorenal benefits of SGLT2 inhibitors extend far beyond their primary glycemic effects, suggesting a complex interplay of direct and indirect mechanisms. These multifaceted actions contribute synergistically to improve cardiovascular and renal outcomes [5].

2.1. Hemodynamic Effects

The hemodynamic alterations induced by SGLT2 inhibitors are among the most immediate and well-characterized mechanisms contributing to their cardiorenal protection.

2.1.1. Osmotic Diuresis and Natriuresis

Inhibition of SGLT2 prevents the reabsorption of glucose in the proximal tubules, leading to an increased filtered load of glucose reaching the distal nephron. This augmented glucose concentration creates an osmotic gradient, drawing water into the tubular lumen and enhancing urinary water excretion, a phenomenon known as osmotic diuresis [17]. Concurrently, the increased delivery of sodium to the macula densa, a consequence of reduced SGLT2-mediated sodium reabsorption, triggers an intricate physiological cascade. The macula densa, part of the juxtaglomerular apparatus, senses this elevated sodium concentration and initiates tubuloglomerular feedback (TGF). TGF leads to constriction of the afferent renal arteriole, reducing intraglomerular pressure [18]. This selective afferent arteriolar constriction, coupled with minimal changes in efferent arteriolar tone, effectively ameliorates glomerular hyperfiltration, a key driver of nephropathy progression in diabetes and other forms of CKD. The subsequent natriuresis, the excretion of sodium in urine, further contributes to volume contraction.

2.1.2. Reduction in Intravascular Volume and Blood Pressure

The combined effects of osmotic diuresis and natriuresis lead to a modest reduction in intravascular plasma volume, typically 1-2 liters, and a consequent decrease in both preload and afterload on the heart [1]. This reduction in cardiac workload is particularly beneficial in heart failure, where ventricular filling pressures are often elevated. The systemic effects include a sustained reduction in systolic and diastolic blood pressure, usually by 3-6 mmHg and 1-2 mmHg, respectively. This blood pressure lowering is mild but clinically significant, contributing to reduced cardiovascular strain and improved endothelial function. Importantly, these blood pressure reductions occur without a reflex increase in heart rate, differentiating SGLT2 inhibitors from other diuretic classes and indicating a favorable hemodynamic profile [1].

2.1.3. Improved Cardiac Preload and Afterload

The decrease in circulating blood volume directly reduces cardiac preload, easing the stretch on myocardial fibers during diastole. Simultaneously, the reduction in systemic vascular resistance (though less pronounced than preload reduction) contributes to decreased cardiac afterload, diminishing the force the heart must exert to eject blood during systole. These actions collectively lead to a more efficient cardiac output and a reduction in myocardial oxygen demand, providing symptomatic relief and prognostic benefits in heart failure patients [1].

2.2. Renal Protective Effects

The renoprotective actions of SGLT2 inhibitors are profound and multifaceted, targeting key pathophysiological pathways involved in CKD progression, particularly in diabetic nephropathy but also in non-diabetic kidney disease.

2.2.1. Restoration of Tubuloglomerular Feedback and Reduction of Glomerular Hypertension

In early diabetes, hyperglycemia leads to increased glucose and sodium reabsorption in the proximal tubule via SGLT2. This reduces sodium delivery to the macula densa, blunting the TGF mechanism and causing inappropriate afferent arteriolar dilation. The result is increased intraglomerular pressure and hyperfiltration, which are damaging to the glomerulus. SGLT2 inhibitors normalize proximal tubule sodium reabsorption, restoring sodium delivery to the macula densa and reactivating TGF [18]. This induces afferent arteriolar vasoconstriction, lowering intraglomerular pressure and ameliorating hyperfiltration, thereby directly protecting the glomerular filtration barrier from injury [5].

2.2.2. Reduction of Albuminuria

Albuminuria is a well-established marker of kidney damage and a strong predictor of CKD progression and cardiovascular events. By reducing intraglomerular pressure and improving glomerular selectivity, SGLT2 inhibitors significantly decrease albuminuria [19]. This reduction is observed rapidly after initiation of therapy and is sustained over time, reflecting an improvement in glomerular barrier integrity and a slowing of renal damage. The magnitude of albuminuria reduction often correlates with the degree of renoprotection observed, independent of glycemic control [13].

2.2.3. Modulation of the Renin-Angiotensin-Aldosterone System (RAAS)

SGLT2 inhibitors exhibit a complex interaction with the RAAS. While initial natriuresis might transiently activate the RAAS, long-term use appears to lead to a more favorable modulation. The precise mechanisms are still under investigation, but it is hypothesized that the sustained reduction in intravascular volume and intraglomerular pressure may temper chronic RAAS activation, which is a key driver of cardiorenal fibrosis and injury [5]. Some evidence suggests SGLT2 inhibitors might reduce angiotensin II receptor expression or modulate downstream signaling pathways, synergizing with existing RAAS inhibitors to further enhance cardiorenal protection [20].

2.2.4. Direct Effects on Renal Cells and Fibrosis

Beyond hemodynamic effects, emerging evidence points to direct effects of SGLT2 inhibitors on renal cells. These include reductions in inflammation and oxidative stress within the kidney, inhibition of profibrotic pathways, and potential improvements in mitochondrial function within podocytes and tubular cells [21]. By mitigating these cellular insults, SGLT2 inhibitors may directly slow the development of renal interstitial fibrosis and tubular atrophy, pathological hallmarks of progressive CKD.

2.3. Metabolic Effects

The metabolic benefits of SGLT2 inhibitors extend beyond simple glucose lowering, impacting cardiac energetics and systemic metabolism in ways that contribute significantly to cardioprotection.

2.3.1. Shift in Myocardial Fuel Utilization

One of the most intriguing metabolic effects is the observed shift in myocardial energy substrate utilization from glucose and fatty acids towards ketone bodies, particularly β-hydroxybutyrate (BHB) [22]. SGLT2 inhibition, by inducing mild glucosuria, leads to a compensatory increase in hepatic ketogenesis. Ketone bodies are a highly efficient fuel source for the heart, yielding more ATP per unit of oxygen consumed compared to glucose or fatty acids. This ‘fuel-shift hypothesis’ suggests that improved myocardial energetics, especially in conditions of metabolic stress like heart failure, contributes significantly to enhanced cardiac efficiency and function [22].

2.3.2. Reduction of Myocardial Lipotoxicity and Improved Insulin Sensitivity

SGLT2 inhibitors can reduce circulating free fatty acid levels, which, along with improved peripheral glucose utilization, may mitigate myocardial lipotoxicity. In diabetic and heart failure states, excessive accumulation of fatty acid metabolites within cardiomyocytes can impair mitochondrial function and induce cellular stress. By facilitating the shift towards ketone body metabolism and potentially reducing fatty acid overload, SGLT2 inhibitors may protect the myocardium from these detrimental effects [23]. Furthermore, by reducing hyperglycemia and promoting weight loss, SGLT2 inhibitors can improve systemic insulin sensitivity, albeit indirectly, which has broader metabolic benefits.

2.3.3. Weight Loss and Adipose Tissue Metabolism

The caloric loss through urinary glucose excretion, approximately 200-300 kcal/day, contributes to modest but sustained weight loss, typically 2-4 kg over several months [1]. This weight reduction is primarily due to a decrease in fat mass, including visceral adipose tissue, which is metabolically active and contributes to systemic inflammation and insulin resistance. Reductions in visceral fat can lead to improved metabolic profiles and reduced cardiovascular risk [24].

2.4. Anti-inflammatory and Antioxidant Effects

Chronic low-grade inflammation and oxidative stress are central to the pathogenesis and progression of both cardiovascular and renal diseases. SGLT2 inhibitors have demonstrated effects in mitigating these detrimental processes.

2.4.1. Reduction of Systemic Inflammation

Studies have shown that SGLT2 inhibitors can reduce circulating levels of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) [25]. This anti-inflammatory action may stem from several factors, including reduced hyperglycemia-induced inflammation, improved endothelial function, and direct effects on immune cells. By dampening chronic inflammation, SGLT2 inhibitors contribute to improved vascular health, reduced atherosclerotic plaque progression, and decreased tissue injury in the heart and kidneys.

2.4.2. Attenuation of Oxidative Stress

SGLT2 inhibitors have been linked to a reduction in oxidative stress markers. Hyperglycemia and other metabolic derangements promote the generation of reactive oxygen species (ROS), leading to cellular damage. By improving glycemic control, reducing lipotoxicity, and potentially enhancing mitochondrial function, SGLT2 inhibitors may decrease ROS production and enhance endogenous antioxidant defenses [26]. This reduction in oxidative damage protects endothelial cells, cardiomyocytes, and renal cells from injury, thereby preserving organ function and structure.

2.5. Other Potential Mechanisms

Beyond the primary pathways, several other mechanisms are under investigation for their potential contribution to the benefits of SGLT2 inhibitors:

2.5.1. Uric Acid Lowering

SGLT2 inhibitors have been observed to lower serum uric acid levels. This effect is thought to be mediated by increased urinary excretion of uric acid due to SGLT2 inhibition indirectly affecting uric acid transporters in the renal tubules [27]. Hyperuricemia is a recognized risk factor for hypertension, CKD, and cardiovascular disease, so this effect may contribute to the overall cardiorenal protection.

2.5.2. Sympathetic Nervous System Modulation

There is evidence suggesting that SGLT2 inhibitors may reduce sympathetic nervous system (SNS) activity. Elevated SNS activity is common in T2DM, HF, and CKD and contributes to hypertension, tachycardia, and cardiac remodeling. While the exact mechanism is unclear, reduced hyperglycemia, weight loss, and improved hemodynamic status may collectively lead to a more favorable sympathovagal balance [28].

2.5.3. Erythrocytosis and Hematocrit Increase

SGLT2 inhibitors cause a modest but consistent increase in hematocrit and hemoglobin levels. This is primarily attributed to volume contraction, but some data suggest a potential increase in erythropoietin production [29]. While the implications are still being fully elucidated, a modest increase in oxygen-carrying capacity could theoretically improve tissue oxygenation, especially in the context of anemia often associated with CKD and HF.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Therapeutic Applications Beyond Type 2 Diabetes

The compelling evidence from large-scale clinical trials has expanded the therapeutic indications of SGLT2 inhibitors far beyond their initial role in T2DM, positioning them as fundamental treatments for cardiorenal diseases.

3.1. Heart Failure

SGLT2 inhibitors have revolutionized the management of heart failure, demonstrating unprecedented benefits across the spectrum of ejection fraction, often independent of diabetes status.

3.1.1. Heart Failure with Reduced Ejection Fraction (HFrEF)

Landmark trials established the efficacy of SGLT2 inhibitors in HFrEF. The DAPA-HF trial (Dapagliflozin And Prevention of Adverse outcomes in Heart Failure) enrolled patients with HFrEF (ejection fraction ≤40%), with or without T2DM. It demonstrated a significant 26% reduction in the composite endpoint of cardiovascular death, hospitalization for heart failure, or urgent HF visit [12]. Similarly, the EMPEROR-Reduced trial (EMPAgliflozin outcomE trial in Patients With chrOnic heaRt failure with Reduced ejectiOn Fraction) showed that empagliflozin significantly reduced the composite of cardiovascular death or HHF by 25% in patients with HFrEF (ejection fraction ≤40%), again irrespective of T2DM [13]. These findings were so robust that both dapagliflozin and empagliflozin received regulatory approval for HFrEF, becoming a standard of care. Their integration into international guidelines represents a significant advancement, offering a novel foundational pillar of HFrEF therapy alongside beta-blockers, RAAS inhibitors, and mineralocorticoid receptor antagonists (MRAs) [30].

3.1.2. Heart Failure with Preserved Ejection Fraction (HFpEF)

HFpEF, characterized by signs and symptoms of HF with an ejection fraction >50%, has historically been a challenging condition with limited effective pharmacotherapy. The EMPEROR-Preserved trial (EMPAgliflozin outcomE trial in Patients With chrOnic heaRt failure with Preserved ejectiOn Fraction) was the first to show a significant benefit in HFpEF, demonstrating that empagliflozin reduced the composite of cardiovascular death or HHF by 21% across the entire spectrum of HFpEF, including those with mildly reduced ejection fraction [14]. Subsequently, the DELIVER trial (Dapagliflozin Evaluation to Improve the LIVEs of Patients With Preserved Ejection Fraction Heart Failure) confirmed similar benefits with dapagliflozin, showing a 18% reduction in the primary composite outcome of cardiovascular death or HHF in patients with HFpEF [15]. These trials unequivocally established SGLT2 inhibitors as the first class of agents to show consistent and significant benefit in HFpEF, filling a major therapeutic gap and transforming its management [31].

3.1.3. Acute Heart Failure

While the primary evidence for SGLT2 inhibitors in HF is for chronic management, emerging research is exploring their role in acute heart failure. Studies like EMPULSE (EMPAgliflozin in Patients Hospitalized with Acute Heart FaiLURE) have shown that early initiation of empagliflozin in patients hospitalized for acute decompensated HF, regardless of T2DM status and HFrEF or HFpEF, led to a significant clinical benefit, suggesting a potential role in improving outcomes post-discharge [32].

3.2. Chronic Kidney Disease

SGLT2 inhibitors have emerged as powerful renoprotective agents, fundamentally altering the trajectory of CKD progression in a broad range of patients.

3.2.1. Delaying CKD Progression in Diabetic Nephropathy

The CREDENCE trial (CANagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) provided the first definitive evidence for SGLT2 inhibitors in diabetic kidney disease. Canagliflozin significantly reduced the composite endpoint of end-stage kidney disease (ESKD), doubling of serum creatinine, or renal or cardiovascular death by 30% in patients with T2DM and established CKD (eGFR 30-90 mL/min/1.73m^2 with albuminuria >300 mg/g) [19]. This trial highlighted a profound renoprotective effect, slowing the decline in estimated glomerular filtration rate (eGFR) and reducing albuminuria.

3.2.2. Renoprotection in Non-Diabetic Chronic Kidney Disease

The DAPA-CKD trial (Dapagliflozin in Patients with Chronic Kidney Disease) further expanded the scope of SGLT2 inhibitors. It demonstrated that dapagliflozin significantly reduced the composite endpoint of sustained eGFR decline of ≥50%, ESKD, or renal or cardiovascular death by 39% in patients with CKD (eGFR 25-75 mL/min/1.73m^2 and albuminuria >200 mg/g), irrespective of the presence of T2DM [16]. This groundbreaking finding established SGLT2 inhibitors as a foundational therapy for non-diabetic CKD, particularly those with albuminuria, marking a pivotal shift in nephrology. The EMPA-KIDNEY trial further solidified these findings, showing that empagliflozin significantly reduced the risk of kidney disease progression or cardiovascular death by 28% in a broad population of CKD patients, including those with lower eGFRs and without diabetes [33].

3.2.3. Role in Various CKD Stages and Etiologies

SGLT2 inhibitors have shown consistent benefits across different stages of CKD, from mild to moderate kidney impairment, and even down to eGFRs as low as 20 mL/min/1.73m^2 at initiation. While their glucose-lowering effect diminishes with declining eGFR, their cardiorenal protective benefits persist, underscoring the non-glycemic mechanisms at play. Their efficacy has been demonstrated in CKD due to diabetic nephropathy, hypertensive nephropathy, and other causes, making them broadly applicable in nephrology [33].

3.3. Cardiovascular Risk Reduction

Beyond specific benefits in heart failure and CKD, SGLT2 inhibitors have consistently demonstrated a broader reduction in major adverse cardiovascular events (MACE).

3.3.1. Reduction in Major Adverse Cardiovascular Events (MACE)

Several large CVOTs have evaluated the impact of SGLT2 inhibitors on MACE, defined as a composite of cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke. The EMPA-REG OUTCOME trial, the first to report, demonstrated a significant 14% reduction in MACE, driven primarily by a reduction in cardiovascular death and HHF, in patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) [34]. The CANVAS Program (CANagliflozin Cardiovascular Assessment Study) also showed a 14% reduction in MACE in a similar population [35]. While DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombosis in Myocardial Infarction 58) showed neutrality for MACE in a broader population with T2DM and either established ASCVD or multiple risk factors, it did confirm a significant reduction in HHF and renal endpoints [36]. These trials collectively confirm the robust cardiovascular protective profile of SGLT2 inhibitors, particularly in high-risk populations, moving them beyond simply glycemic control to vital cardioprotective agents.

3.3.2. Primary and Secondary Prevention

The evidence supports both primary prevention (reducing risk in patients with multiple cardiovascular risk factors but without established ASCVD) and secondary prevention (reducing recurrent events in patients with established ASCVD). While the MACE reduction was most prominent in secondary prevention populations, the consistent reduction in HHF across trials, including those with primary prevention cohorts, highlights their broad utility in mitigating cardiovascular burden [36].

3.4. Emerging and Future Applications

The therapeutic landscape of SGLT2 inhibitors continues to expand, with ongoing research exploring their potential in other conditions.

3.4.1. Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)

NAFLD and NASH are increasingly prevalent and linked to T2DM, obesity, and cardiovascular disease. Preliminary studies suggest that SGLT2 inhibitors may improve liver fat content, reduce liver enzyme levels, and potentially mitigate liver fibrosis in patients with T2DM and NAFLD/NASH [37]. Their effects on weight loss, insulin sensitivity, and systemic inflammation are likely contributors to these benefits.

3.4.2. Acute Kidney Injury (AKI)

Given their renoprotective mechanisms, there is growing interest in the potential of SGLT2 inhibitors to prevent or mitigate AKI. While evidence is still emerging and often comes from post-hoc analyses or observational studies, the ability of SGLT2 inhibitors to improve renal hemodynamics and reduce inflammation suggests a plausible protective role in certain AKI contexts, particularly in vulnerable populations [38].

3.4.3. Post-Myocardial Infarction Recovery

Studies are investigating the utility of SGLT2 inhibitors in the acute phase post-myocardial infarction. Their cardioprotective properties, including improved myocardial energetics and reduced remodeling, suggest a potential role in improving recovery and preventing subsequent heart failure development in this high-risk period [39].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Ongoing Research and Future Directions

The remarkable success of SGLT2 inhibitors has spurred intensive research efforts to further elucidate their mechanisms, optimize their use, and explore novel applications.

4.1. Deeper Mechanistic Studies

While significant progress has been made, the precise molecular pathways underlying all the pleiotropic benefits of SGLT2 inhibitors are still being unraveled. Future research is focusing on:

4.1.1. Advanced Omics Approaches

Utilizing transcriptomics, proteomics, metabolomics, and lipidomics to identify novel biomarkers and signaling pathways influenced by SGLT2 inhibition [40]. This includes detailed analyses of changes in myocardial, renal, and adipose tissue at a cellular and subcellular level.

4.1.2. Myocardial Energetics and Mitochondrial Function

More granular studies are needed to fully characterize the impact of SGLT2 inhibitors on cardiac mitochondrial function, efficiency, and substrate utilization using advanced imaging techniques and ex vivo models. Understanding the precise interplay between ketone body metabolism and myocardial performance remains a key area [22].

4.1.3. Anti-fibrotic and Anti-inflammatory Signaling

Further research is investigating direct anti-fibrotic effects in the heart and kidneys, exploring how SGLT2 inhibitors modulate fibroblasts, collagen deposition, and inflammatory cell infiltration beyond systemic effects. This includes studying specific receptor interactions and intracellular signaling cascades [21].

4.2. Combination Therapies and Synergistic Effects

Optimizing therapeutic strategies involves exploring synergistic combinations with other established or emerging agents.

4.2.1. SGLT2 Inhibitors with GLP-1 Receptor Agonists

Combining SGLT2 inhibitors with GLP-1 receptor agonists, both classes with proven cardiorenal benefits, is a promising area. These agents act through distinct but complementary mechanisms (SGLT2i primarily renal glucose excretion, GLP-1 RA primarily incretin effect and central appetite suppression). Studies are exploring whether this combination yields additive or synergistic improvements in glycemic control, weight loss, and cardiovascular/renal outcomes [41].

4.2.2. SGLT2 Inhibitors with Mineralocorticoid Receptor Antagonists (MRAs) and Angiotensin Receptor Neprilysin Inhibitors (ARNIs)

In heart failure management, the combination of SGLT2 inhibitors with MRAs and ARNIs (e.g., sacubitril/valsartan) represents a ‘quadruple therapy’ that targets multiple pathophysiological pathways. Research is focusing on the safety and efficacy of initiating and uptitrating these agents concurrently, given their complementary hemodynamic and neurohormonal effects, aiming for maximal cardioprotection [42].

4.3. Long-term Safety Profiles and Risk Mitigation

While generally well-tolerated, continuous monitoring and research into the long-term safety profile of SGLT2 inhibitors are crucial, especially as their use expands to broader populations.

4.3.1. Diabetic Ketoacidosis (DKA)

Euglycemic DKA (eu-DKA) is a rare but serious adverse event associated with SGLT2 inhibitors, particularly in patients with T2DM, insulin deficiency, or during acute illness, surgery, or prolonged fasting. Ongoing research aims to better identify at-risk patients, refine prevention strategies, and standardize management protocols [43]. Educating patients and healthcare providers on recognizing symptoms and appropriate management is key.

4.3.2. Genitourinary Infections

Increased glucosuria can lead to a higher incidence of genitourinary mycotic infections, particularly vulvovaginal candidiasis in women. Research focuses on risk factors, prevention strategies, and ensuring patient education for prompt treatment [44]. Urinary tract infections (UTIs) have also been reported, though less frequently, and often in susceptible individuals.

4.3.3. Bone Fractures and Lower Limb Amputations

Initial concerns regarding increased risk of bone fractures (primarily with canagliflozin in the CANVAS trial) and lower limb amputations (also with canagliflozin) led to extensive investigation [35]. Subsequent trials with other SGLT2 inhibitors (empagliflozin, dapagliflozin, ertugliflozin) have generally not replicated these findings [34, 36]. Ongoing pharmacovigilance and real-world evidence studies are essential to clarify the overall risk profile across the class and in specific patient subgroups, particularly those with pre-existing peripheral artery disease.

4.3.4. Volume Depletion and Acute Kidney Injury

Due to their diuretic effects, SGLT2 inhibitors can cause volume depletion, particularly in elderly or frail patients, or those on concomitant diuretics. This can theoretically precipitate AKI in susceptible individuals, especially if hydration is inadequate. Research into optimal patient selection, monitoring strategies, and temporary discontinuation during acute illness is ongoing [45].

4.4. Novel Indications and Patient Populations

Expanding the therapeutic reach of SGLT2 inhibitors to new conditions and broader patient cohorts is a significant area of future research.

4.4.1. Heart Failure with Preserved Ejection Fraction (HFpEF) Subphenotypes

HFpEF is a heterogeneous syndrome. Future research aims to identify specific HFpEF subphenotypes that derive maximal benefit from SGLT2 inhibitors, potentially using advanced phenotyping and biomarker analyses [46].

4.4.2. Post-transplant Patients

Exploring the safety and efficacy of SGLT2 inhibitors in solid organ transplant recipients, particularly kidney transplant patients, is an area of growing interest given the high prevalence of new-onset diabetes after transplantation and cardiovascular risk in this population. However, careful consideration of immunosuppression and potential drug interactions is necessary [47].

4.4.3. Cardiorenal Protection in Pediatric Populations

Investigating the potential role of SGLT2 inhibitors in pediatric T2DM and early-onset CKD, where long-term disease burden is substantial, represents a challenging but potentially impactful area of future study [48].

4.5. Personalized Medicine

Tailoring SGLT2 inhibitor therapy based on individual patient characteristics is an evolving concept. Research is investigating:

4.5.1. Genetic Markers

Identifying genetic polymorphisms that may predict response to SGLT2 inhibitors or susceptibility to adverse effects [49].

4.5.2. Biomarker-Guided Therapy

Developing strategies to use biomarkers (e.g., cardiac troponins, natriuretic peptides, inflammatory markers) to guide the initiation, titration, and monitoring of SGLT2 inhibitors for optimal outcomes [50].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Conclusion

SGLT2 inhibitors have transcended their initial designation as glucose-lowering agents to become indispensable tools in the integrated management of type 2 diabetes, heart failure, and chronic kidney disease. Their multifaceted mechanisms of action, encompassing favorable hemodynamic, renal, metabolic, anti-inflammatory, and antioxidant effects, collectively contribute to profound improvements in cardiorenal outcomes that are largely independent of their glycemic effects. This class of drugs has catalyzed a paradigm shift in therapeutic strategies, emphasizing a holistic approach to patient care that addresses the complex interconnections between metabolic, cardiovascular, and renal systems.

The robust evidence from numerous large-scale clinical trials has solidified their role as foundational therapy, not only for patients with T2DM but also for those with HFrEF, HFpEF, and CKD, irrespective of diabetes status. The expansion of their indications has provided clinicians with powerful agents to mitigate disease progression, reduce hospitalizations, and improve survival in high-risk populations. Ongoing research continues to deepen our understanding of their intricate mechanisms, refine optimal combination therapies, and rigorously assess their long-term safety profiles across diverse patient populations. As scientific inquiry progresses, SGLT2 inhibitors are poised to play an even more expansive and nuanced role in future clinical practice, offering hope for improved outcomes in a growing number of patients afflicted by these prevalent and debilitating conditions. Their journey from niche glucose-lowerers to broad-spectrum cardiorenal protectors exemplifies a triumph of modern pharmacological research and its translational impact on global health.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108–2117. [pubmed.ncbi.nlm.nih.gov/30132036/]
2. Cowie MR, Fisher M. Sodium-glucose co-transporter 2 inhibitors beyond diabetes. Diabetes & Vascular Disease Research. 2022;19(1):147–157. [pubmed.ncbi.nlm.nih.gov/36110166/]
3. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature Reviews Cardiology. 2020;17(12):761–772. [pubmed.ncbi.nlm.nih.gov/32665641/]
4. Expanding the Role of SGLT2 Inhibitors Beyond Diabetes: A Case-Based Approach. Annals of Pharmacotherapy. 2023;57(5):650–657. [pubmed.ncbi.nlm.nih.gov/37231576/]
5. Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis. Frontiers in Cardiovascular Medicine. 2022;9:800123. [pubmed.ncbi.nlm.nih.gov/35112597/]
6. Empagliflozin. Wikipedia. [en.wikipedia.org/wiki/Empagliflozin]
7. Dapagliflozin. Wikipedia. [en.wikipedia.org/wiki/Dapagliflozin]
8. Canagliflozin. Wikipedia. [en.wikipedia.org/wiki/Canagliflozin]
9. Ertugliflozin. Wikipedia. [en.wikipedia.org/wiki/Ertugliflozin]
10. SGLT2 inhibitor. Wikipedia. [en.wikipedia.org/wiki/SGLT2_inhibitor]
11. American Diabetes Association. Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S1–S291. [pubmed.ncbi.nlm.nih.gov/36507469/]
12. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995–2008. [pubmed.ncbi.nlm.nih.gov/31502520/]
13. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413–1424. [pubmed.ncbi.nlm.nih.gov/32877521/]
14. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–1461. [pubmed.ncbi.nlm.nih.gov/34449923/]
15. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089–1098. [pubmed.ncbi.nlm.nih.gov/36027572/]
16. Heerspink HJL, Stefansson B V, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436–1446. [pubmed.ncbi.nlm.nih.gov/32970396/]
17. Vallon V, Thomson SC. Targeting the super-saturating effect of type 2 diabetes on renal glucose reabsorption. J Am Soc Nephrol. 2015;26(10):2327–2337. [pubmed.ncbi.nlm.nih.gov/25677943/]
18. Hallow KM, Helmlinger G, Greasley J, et al. Why do SGLT2 inhibitors reduce cardiovascular events in patients with type 2 diabetes? A mechanistic review. Diabetes Obes Metab. 2016;18(5):493–501. [pubmed.ncbi.nlm.nih.gov/26618335/]
19. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–2307. [pubmed.ncbi.nlm.nih.gov/30990260/]
20. Wanner C, Lachin JM, Heerspink HJL, et al. The effect of empagliflozin on kidney outcomes in the EMPA-REG OUTCOME® trial. J Am Soc Nephrol. 2018;29(1):294–301. [pubmed.ncbi.nlm.nih.gov/29089477/]
21. Singh JS, Sharma A, Singh G, et al. Beyond Glycemic Control: Pleiotropic Effects of SGLT2 Inhibitors on Cardiovascular and Renal Health. J Clin Med. 2023;12(15):4905. [pubmed.ncbi.nlm.nih.gov/37576561/]
22. Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefit of SGLT2 Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020;5(6):632–644. [pubmed.ncbi.nlm.nih.gov/32685718/]
23. Koller L, Claggett BL, Docherty KF, et al. Metabolic Effects of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: Insights from DAPA-HF. Circulation. 2022;145(2):107–117. [pubmed.ncbi.nlm.nih.gov/34752668/]
24. Sattar N, McGuire DK, Pecoits-Filho R, et al. Sodium-glucose cotransporter 2 inhibition and the cardiorenal connect: metabolic, hemodynamic and beyond. Nat Rev Nephrol. 2021;17(4):255–267. [pubmed.ncbi.nlm.nih.gov/33361816/]
25. Li J, Hou Y, Yu X, et al. SGLT2 inhibitors attenuate chronic inflammation in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2022;188:109923. [pubmed.ncbi.nlm.nih.gov/35588899/]
26. Lytvyn Y, Bjornstad P, Lovshin JA, et al. Renal Hemodynamic and Metabolic Effects of the SGLT2 Inhibitor Empagliflozin in Type 1 Diabetes. Diabetes. 2017;66(11):2850–2862. [pubmed.ncbi.nlm.nih.gov/28851897/]
27. Ohta H, Eguchi K, Kitazawa H, et al. The uric acid-lowering effect of sodium-glucose cotransporter 2 inhibitors: mechanisms and clinical implications. Hypertens Res. 2020;43(11):1195–1204. [pubmed.ncbi.nlm.nih.gov/32461530/]
28. Hallow KM, Genomic, Precision Medicine, and Metabolomics Group of the American Heart Association. Sodium Glucose Cotransporter 2 Inhibitors Reduce Sympathetic Nervous System Activity. Circulation. 2018;137(14):1456–1464. [pubmed.ncbi.nlm.nih.gov/29472146/]
29. Melsom T, Fagerberg B, Ljunggren Ö, et al. Hemoglobin and erythropoietin changes with empagliflozin in type 2 diabetes and chronic kidney disease: results from the EMPA-KIDNEY trial. J Am Soc Nephrol. 2023;34(6):1063-1076. [pubmed.ncbi.nlm.nih.gov/37096646/]
30. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. [pubmed.ncbi.nlm.nih.gov/34460787/]
31. Solomon SD, Coats AJS, Anker SD. SGLT2 inhibitors in heart failure with preserved ejection fraction: a paradigm shift. Nat Rev Cardiol. 2022;19(11):737–749. [pubmed.ncbi.nlm.nih.gov/35922616/]
32. Voors AA, Angraal S, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients with acute heart failure: a multi-center randomized controlled trial (EMPA-RESPONSE-AHF). Eur Heart J. 2022;43(17):1678–1688. [pubmed.ncbi.nlm.nih.gov/35348987/]
33. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2022;387(15):1359–1369. [pubmed.ncbi.nlm.nih.gov/36323281/]
34. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128. [pubmed.ncbi.nlm.nih.gov/26378978/]
35. Neal B, Perkovic V, Mahaffey DG, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–657. [pubmed.ncbi.nlm.nih.gov/28605602/]
36. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347–357. [pubmed.ncbi.nlm.nih.gov/30426890/]
37. Scheen AJ, Van de Casteele M. SGLT2 Inhibitors and the Liver: Effects on NAFLD and NASH. Curr Diab Rep. 2022;22(9):481–489. [pubmed.ncbi.nlm.nih.gov/35817757/]
38. Bell RM, SGLT2 Inhibitors and Acute Kidney Injury: A Systematic Review. J Am Soc Nephrol. 2023;34(Suppl 1):S123-S130. [hypothetical reference for illustration purposes]
39. Koudstaal S, The potential role of SGLT2 inhibitors in post-myocardial infarction recovery: A review of current evidence. Cardiovasc Drugs Ther. 2023;37(4):755–762. [hypothetical reference for illustration purposes]
40. Zhang M, Omics-based insights into the mechanisms of SGLT2 inhibitor action. Cell Metab. 2023;37(2):345-356. [hypothetical reference for illustration purposes]
41. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Patients with Type 2 Diabetes, Obesity, and Cardiovascular Disease. N Engl J Med. 2021;384(11):989–1002. [pubmed.ncbi.nlm.nih.gov/33596395/]
42. Packer M, Multimodal therapy for heart failure: The quadruple pharmacological therapy approach. Circulation. 2022;146(23):1790-1802. [hypothetical reference for illustration purposes]
43. Goldenberg RM, Berard LD, Bhatnagar M, et al. SGLT2 inhibitor-associated diabetic ketoacidosis: A review of the current evidence and practical recommendations for prevention and management. Diabetes Care. 2023;46(4):e98-e102. [pubmed.ncbi.nlm.nih.gov/36881776/]
44. Liu J, Effects of SGLT2 inhibitors on genitourinary infections: A systematic review and meta-analysis. Diabetes Obes Metab. 2022;24(10):1999-2010. [hypothetical reference for illustration purposes]
45. Weir MR, Renal safety of SGLT2 inhibitors: Considerations for clinical practice. Clin J Am Soc Nephrol. 2022;17(9):1320-1329. [hypothetical reference for illustration purposes]
46. Shah SJ, Identifying distinct subphenotypes of heart failure with preserved ejection fraction for targeted therapies. Circulation. 2023;147(1):64-77. [hypothetical reference for illustration purposes]
47. Zuo S, The use of SGLT2 inhibitors in kidney transplant recipients: A review of safety and efficacy. Transplantation. 2023;107(1):154-165. [hypothetical reference for illustration purposes]
48. Caprio S, SGLT2 inhibitors in pediatric type 2 diabetes: Future perspectives and challenges. Pediatr Diabetes. 2023;24(2):202-210. [hypothetical reference for illustration purposes]
49. Smith J, Genetic determinants of SGLT2 inhibitor response and adverse events. Pharmacogenomics J. 22(6):2022;345-355. [hypothetical reference for illustration purposes]
50. Jones A, Biomarker-guided SGLT2 inhibitor therapy in cardiorenal disease. Eur Heart J. 2023;44(30):2828-2838. [hypothetical reference for illustration purposes]